[go: up one dir, main page]

MA56386B1 - Polythérapie comprenant de l'acétyl-leucine et du miglustat pour le traitement d'une maladie lysosomale - Google Patents

Polythérapie comprenant de l'acétyl-leucine et du miglustat pour le traitement d'une maladie lysosomale

Info

Publication number
MA56386B1
MA56386B1 MA56386A MA56386A MA56386B1 MA 56386 B1 MA56386 B1 MA 56386B1 MA 56386 A MA56386 A MA 56386A MA 56386 A MA56386 A MA 56386A MA 56386 B1 MA56386 B1 MA 56386B1
Authority
MA
Morocco
Prior art keywords
miglustat
leucine
acetyl
treatment
lysosomal storage
Prior art date
Application number
MA56386A
Other languages
English (en)
Other versions
MA56386A (fr
Inventor
Michael Strupp
Mallory Factor
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MA56386A publication Critical patent/MA56386A/fr
Publication of MA56386B1 publication Critical patent/MA56386B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des méthodes de traitement de maladies lysosomales (LSD) chez un sujet qui en a besoin par l'administration au sujet d'une association d'acétyl-leucine et de miglustat, le sujet étant naïf en matière de traitement avec le miglustat.
MA56386A 2019-06-28 2020-06-26 Polythérapie comprenant de l'acétyl-leucine et du miglustat pour le traitement d'une maladie lysosomale MA56386B1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962868383P 2019-06-28 2019-06-28
US201962931003P 2019-11-05 2019-11-05
EP20736444.9A EP3989962B1 (fr) 2019-06-28 2020-06-26 Polythérapie comprenant de l'acétyl-leucine et du miglustat pour le traitement d'une maladie lysosomale
PCT/IB2020/056096 WO2020261230A1 (fr) 2019-06-28 2020-06-26 Polythérapie comprenant de l'acétyl-leucine et du miglustat

Publications (2)

Publication Number Publication Date
MA56386A MA56386A (fr) 2022-05-04
MA56386B1 true MA56386B1 (fr) 2025-10-31

Family

ID=71452519

Family Applications (1)

Application Number Title Priority Date Filing Date
MA56386A MA56386B1 (fr) 2019-06-28 2020-06-26 Polythérapie comprenant de l'acétyl-leucine et du miglustat pour le traitement d'une maladie lysosomale

Country Status (15)

Country Link
US (1) US20220362189A1 (fr)
EP (2) EP4650003A3 (fr)
DK (1) DK3989962T3 (fr)
ES (1) ES3048174T3 (fr)
FI (1) FI3989962T3 (fr)
HR (1) HRP20251256T1 (fr)
LT (1) LT3989962T (fr)
MA (1) MA56386B1 (fr)
MD (1) MD3989962T2 (fr)
PL (1) PL3989962T3 (fr)
PT (1) PT3989962T (fr)
RS (1) RS67283B1 (fr)
SI (1) SI3989962T1 (fr)
SM (1) SMT202500369T1 (fr)
WO (1) WO2020261230A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
IL319687A (en) * 2018-12-06 2025-05-01 Intrabio Ltd Deuterated acetyl-leucine analogs
CN118409027B (zh) * 2024-07-02 2024-09-10 成都市食品检验研究院 一种食品中1-脱氧野尻霉素的含量检测方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2588130T3 (en) 2010-06-25 2016-10-24 Shire Human Genetic Therapies Cns delivery of therapeutic agents
MA55947A (fr) 2016-08-11 2022-03-23 Intrabio Ltd Compositions pharmaceutiques et utilisations dirigées vers des troubles d'entreposage lysosomial

Also Published As

Publication number Publication date
WO2020261230A1 (fr) 2020-12-30
LT3989962T (lt) 2025-10-10
EP3989962A1 (fr) 2022-05-04
PT3989962T (pt) 2025-10-09
MA56386A (fr) 2022-05-04
RS67283B1 (sr) 2025-11-28
PL3989962T3 (pl) 2025-11-17
EP4650003A2 (fr) 2025-11-19
EP4650003A3 (fr) 2026-01-21
US20220362189A1 (en) 2022-11-17
SI3989962T1 (sl) 2025-11-28
EP3989962B1 (fr) 2025-08-27
HRP20251256T1 (hr) 2025-12-05
FI3989962T3 (fi) 2025-10-08
SMT202500369T1 (it) 2025-11-10
DK3989962T3 (da) 2025-10-13
MD3989962T2 (ro) 2025-12-31
ES3048174T3 (en) 2025-12-09

Similar Documents

Publication Publication Date Title
MA56386B1 (fr) Polythérapie comprenant de l'acétyl-leucine et du miglustat pour le traitement d'une maladie lysosomale
MA52219B1 (fr) Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak
EA201000441A1 (ru) Водные офтальмологические препараты
CR7330A (es) Procedimiento para tratar enfermedades neovasculares oculares
CY1114815T1 (el) Χορηγηση θεραπευτικων χημικων ενωσεων στον εγκεφαλο και σε αλλους ιστους
AR043188A1 (es) Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias
CL2019003496A1 (es) Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
AR109103A1 (es) Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert
MA44612B1 (fr) Méthodes de traitement de cancers pédiatriques
EA202090564A1 (ru) Способы усиления и/или стабилизации сердечной функции у пациентов с болезнью фабри
MX361741B (es) Tratamientos médicos a base de anamorelina.
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
MX2025001920A (es) Tratamiento de enfermedades y trastornos asociados a las mitocondrias, incluyendo los sintomas de los mismos usando pridopidina
CY1124236T1 (el) Διαλυμα εγχυσης λεβοντοπα
CO2022005113A2 (es) Métodos de tratamiento para modificar la hemodinámica
EA202090242A1 (ru) Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
DE602005009176D1 (de) Behandlung von t-zellen-lymphom mittels 10-propargyl-10-deazaaminopterin
MA58093B1 (fr) Nouveaux analogues d'insuline et leurs utilisations
WO2018044132A3 (fr) Préservatif pour patient souffrant d'un dysfonctionnement érectile
MX2023001881A (es) Tratamiento con ribitol.
DE60138385D1 (de) Heilmittel zur behandlung von erkrankungen des sehnervs
MX2022006083A (es) Metodos para tratar afecciones relacionadas con el receptor s1p1.
AR117861A1 (es) Métodos de reducción de eventos cerebrovasculares en pacientes con enfermedad de fabry
ATE495750T1 (de) Sulfatide zur behandlung von autoimmunkrankheiten
BR112022001814A2 (pt) Métodos de tratamento de câncer multifocal